CIK 0001826667 · Non-accelerated filer<br>Smaller reporting company
TriSalus Life Sciences, Inc.
Sign in to watch- Ticker
- TLSI
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 853009869
- Phone
- 415 336 8917
- Business address
- 6272 WEST 91ST AVENUE, WESTMINSTER, CO, 80031
- Former names
- MedTech Acquisition Corp, MedTech Acquisition Corporation
Securities
- TLSI Common Stock Nasdaq
- TLSIW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,113
- in 3 filings
Net −$4,113. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 26 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-12 | Marshak Richard Chief Commercial Officer | Sale | −1,589 | $4.09 | $6K | 110,816 |
| 2026-03-12 | Stevens Jennifer Chief Regulatory Officer | Sale | −1,552 | $4.09 | $6K | 124,884 |
| 2026-03-11 | Devlin Jodi Chief of Clinical Operations | Sale | −1,162 | $4.13 | $5K | 99,409 |
| 2026-03-11 | Cox Bryan F. Chief of Research | Sale | −1,138 | $4.13 | $5K | 165,461 |
| 2026-03-11 | Marshak Richard Chief Commercial Officer | Sale | −1,449 | $4.13 | $6K | 112,405 |
| 2026-03-11 | Stevens Jennifer Chief Regulatory Officer | Sale | −1,204 | $4.13 | $5K | 126,436 |
| 2026-03-11 | Szela Mary T CEO and President | Sale | −4,358 | $4.13 | $18K | 768,931 |
| 2026-02-23 | Patience David Chief Financial Officer | Purchase | +3,657 | $4.10 | $15K | 268,657 |
| 2026-02-23 | Gordon Gary B. Director | Purchase | +9,756 | $4.10 | $40K | 9,756 |
| 2026-02-23 | Valle William Director | Purchase | +30,487 | $4.10 | $125K | 30,487 |
| 2026-02-23 | Szela Mary T CEO and President | Purchase | +30,487 | $4.10 | $125K | 773,289 |
| 2026-02-23 | Stansky Michael P Director | Purchase | +243,900 | $4.10 | $1000K | 787,132 |
| 2026-02-23 | Stansky Michael P Director | Purchase | +117,198 | $4.10 | $481K | 199,698 |
| 2026-02-04 | Stansky Michael P Director | Grant or award · Director Stock Option (right to buy) | +92,537 | 92,537 | ||
| 2025-11-24 | Devlin Jodi Chief of Clinical Operations | Grant or award | +50,000 | 100,571 | ||
| 2025-11-24 | Devlin Jodi Chief of Clinical Operations | Grant or award · Employee Stock Option (right to buy) | +100,000 | 463,750 | ||
| 2025-11-24 | Marshak Richard Chief Commercial Officer | Grant or award | +60,000 | 113,854 | ||
| 2025-11-24 | Marshak Richard Chief Commercial Officer | Grant or award · Employee Stock Option (right to buy) | +120,000 | 408,937 | ||
| 2025-11-24 | Stevens Jennifer Chief Regulatory Officer | Grant or award | +50,000 | 127,640 | ||
| 2025-11-24 | Stevens Jennifer Chief Regulatory Officer | Grant or award · Employee Stock Option (right to buy) | +100,000 | 323,782 |
Page 3 of 9 · 161 trades